



Press
release

Montpellier (France), July 18, 2018 - 5:45 pm CEST

Progress review of proposed combination of Intrasense and DMS Group

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions, reviews today the progress of exclusive negotiations with DMS Group, for the contribution of DMS Group medical imaging activities to Intrasense, following the announcement of [May 15th](#).

Both companies are finalizing the contribution agreement and the exchange parity, which has taken longer than originally envisaged because of complex mandatory technical procedures for this type of transaction.

Contribution agreement submitted to vote of the shareholders

The board of directors of both companies will validate the contribution agreement and convene the general meetings very soon. A joint press release will then describe definitive parity for contribution.

Intrasense shareholders will be informed of the terms of the transaction long before the annual general meeting, approving the financial statements for the financial year ending on 31 December 2017, which will also approve contribution based in particular on the report of the contribution assessor, and will be made public before the General Meeting.

Following the board of directors meeting, the Intrasense shareholders will be convened to the 2018 annual general meeting, according to the standard forms and with legal and prevailing regulatory requirements. The implementation of the capitalistic operation could be completed in September 2018, after the vote of both general meetings.

Create a champion of French medtechs to boost activity

With very similar and highly complementary strategies – B-to-B, white label –, Intrasense and DMS Group are positioning themselves as providers of high quality services and solutions. Intrasense would then reach very high potential international industrial customers and boost its capability to disseminate Myrian® technology.

Intrasense would ultimately provide innovative software solutions based on Myrian® platform to DMS Imaging equipment offer, which would ensure an important additional volume of activity for its software activities.



Beyond structure mutualization and economies of scale, the proposed combination would also strongly strengthen the growth of Intrasense activities. In the long term, it would also give access to very structuring projects, on a larger scale, and strengthen its innovation capabilities and potential valuation.

About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device called Myrian®, a software platform that facilitates diagnosis, decision-making and therapeutic follow-up and makes them more secure. Thanks to Myrian®, more than 800 health institutions spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies, Myrian® also provides a universal image treatment solution that can be fully integrated in any health information system. Intrasense includes 40 employees among which 20 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and invested more than 10 million euros in Research & Development since its creation.

More information on www.intrasense.fr.

Contacts

Intrasense
Nicolas Reymond
Chief Executive Officer
Montpellier - FRANCE
Tel: +334 67 130 130
investor@intrasense.fr

NewCap
Investor Relations and
Financial Communication
Valentine Brouchet - Pierre Laurent
Tel: +331 44 71 94 96
intrasense@newcap.eu

